Takeda announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board director until June 28, 2024.
Milano Furuta, president of Takeda’s Japan Pharma Business Unit (JPBU), will succeed Saroukos, effective April 1, 2024. Furuta will report to Christophe Weber, president & CEO, and will be based in Tokyo, Japan. As CFO, Furuta will be proposed to the board of directors as a candidate for election to the board, the statement said.
Christophe Weber commented: “On behalf of Takeda’s executive team and board of directors, I would like to thank Costa for his outstanding contributions and leadership. He has been a key driver of Takeda’s transformation and a trusted advisor to me and the board. He has also built a strong finance function and culture that will serve Takeda well for years to come. I wish Costa all the best as he returns to his home country to be closer to his family.”
Saroukos has played a pivotal role in Takeda’s transformation into a global biopharmaceutical company. His leadership during the acquisition and integration of Shire PLC., the largest-ever overseas acquisition by a Japanese company, was a critical factor in the deal’s success, and his financial stewardship has helped position the company for a renewed focus on growth investment and shareholder returns. He joined Takeda in 2015 as the CFO of the EUCAN [Europe and Canada] Business Unit and was appointed global CFO in April 2018, according to the statement.
Prior to joining Takeda in 2010, Furuta worked as an equity research analyst at an investment management firm in the United States. Furuta began his career in 2000 in banking and private equity investment in Japan, where he was involved with several types of financial transactions, including leveraged buyouts and debt restructuring. Before becoming JPBU president, Furuta served as corporate strategy officer and chief of staff at Takeda, and has held multiple leadership roles with the company around the world.
Furuta holds an MBA from The Wharton School of the University of Pennsylvania and a bachelor’s degree in international affairs from Hitotsubashi University in Japan.
“It gives me great confidence to know that Milano, a long-time Takeda colleague, is stepping into this role,” said Weber. “Milano’s global experience and exceptional leadership qualities make him well-equipped to lead our talented finance organization. I look forward to working with Milano more closely to deliver on our commitment to investing in growth and shareholder returns.”
“It has been an honor to serve at Takeda and witness the positive impact we’ve made in the lives of patients. I am immensely proud of our successful transformation into a truly global biopharmaceutical company with a well-managed debt profile, robust cash flow and a long runway of profitable growth ahead. After 20 years working outside of Australia, I’m now looking forward to returning home to be closer to family. I’ve had the pleasure of working closely with Milano as a member of the Takeda Executive Team and I’m fully confident that his experience, financial background and strong leadership capabilities will help to ensure that Takeda remains focused on delivering on its commitments to shareholders,” said Costa Saroukos.
“I am honored and excited to take on the role of CFO of Takeda. I wish Costa all the best on his return to Australia and I look forward to building on his legacy and contributing to Takeda as a global, values-based, R&D-driven biopharmaceutical leader,” said Milano Furuta.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.